Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020;6(1):81. https://doi.org/10.1038/s41572-020-0213-x.
Article
PubMed
Google Scholar
Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol. 2018;154(4):461–6. https://doi.org/10.1001/jamadermatol.2017.5980.
Article
PubMed
Google Scholar
Jockenhöfer F, Wollina U, Salva KA, Benson S, Dissemond J. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol. 2019;180(3):615–20. https://doi.org/10.1111/bjd.16401.
Article
PubMed
Google Scholar
Brocq L, Simon C. Contribution à l’étude du phagédénisme. Bull Soc Méd Hop Paris. 1908;290–307.
Brunsting LA, Goeckerman WH, O’Leary PA. Pyoderma (ecthyma) gangrenosum. Arch Derm Syphilol. 1930;22(4):655–80.
Article
Google Scholar
Marzano AV, Borghi A, Wallach D, Cugno M. A comprehensive review of neutrophilic diseases. Clin Rev Allergy Immunol. 2018;54(1):114–30. https://doi.org/10.1007/s12016-017-8621-8.
CAS
Article
PubMed
Google Scholar
Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23(9):1008–17. https://doi.org/10.1111/j.1468-3083.2009.03199.x.
CAS
Article
PubMed
Google Scholar
Marzano AV, Trevisan V, Galloni C, Alessi E. Fatal bullous pyoderma gangrenosum in a patient with Klinefelter’s syndrome. Acta Derm Venereol. 2008;88(2):158–9. https://doi.org/10.2340/00015555-0346.
Article
PubMed
Google Scholar
Marzano AV, Tourlaki A, Alessi E, Caputo R. Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximab. Clin Exp Dermatol. 2008;33(2):156–9. https://doi.org/10.1111/j.1365-2230.2007.02607.x.
CAS
Article
PubMed
Google Scholar
Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am J Clin Dermatol. 2017;18(4):555–62. https://doi.org/10.1007/s40257-017-0265-1.
Article
PubMed
Google Scholar
Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016;175(5):882–91. https://doi.org/10.1111/bjd.14691.
CAS
Article
PubMed
Google Scholar
Wang EA, Steel A, Luxardi G, et al. Classic ulcerative pyoderma gangrenosum is a T cell-mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies. Front Immunol. 2018;8:1980. https://doi.org/10.3389/fimmu.2017.01980.
CAS
Article
PubMed
PubMed Central
Google Scholar
Antiga E, Maglie R, Volpi W, et al. T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum. Clin Exp Immunol. 2017;189(3):383–91. https://doi.org/10.1111/cei.12989.
CAS
Article
PubMed
PubMed Central
Google Scholar
Ortega-Loayza AG, Nugent WH, Lucero OM, Washington SL, Nunley JR, Walsh SW. Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum. Br J Dermatol. 2018;178(1):e35–6. https://doi.org/10.1111/bjd.15837.
CAS
Article
PubMed
Google Scholar
Ortega-Loayza AG, Friedman MA, Reese AM, et al. Molecular and cellular characterization of pyoderma gangrenosum: implications for the use of gene expression. J Investig Dermatol. 2021. https://doi.org/10.1016/j.jid.2021.08.431.
Article
PubMed
Google Scholar
Marzano AV, Damiani G, Ceccherini I, Berti E, Gattorno M, Cugno M. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017;176(6):1588–98. https://doi.org/10.1111/bjd.15226.
CAS
Article
PubMed
Google Scholar
Marzano AV, Ortega-Loayza AG, Heath M, Morse D, Genovese G, Cugno M. Mechanisms of inflammation in neutrophil-mediated skin diseases. Front Immunol. 2019;10:1059. https://doi.org/10.3389/fimmu.2019.01059.
CAS
Article
PubMed
PubMed Central
Google Scholar
Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821–52. https://doi.org/10.1146/annurev.immunol.23.021704.115835.
CAS
Article
PubMed
Google Scholar
Lu JD, Milakovic M, Ortega-Loayza AG, Marzano AV, Alavi A. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. Expert Opin Investig Drugs. 2020;29(11):1179–85. https://doi.org/10.1080/13543784.2020.1819981.
CAS
Article
PubMed
Google Scholar
Caproni M, Antiga E, Volpi W, et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol. 2015;173(1):275–8. https://doi.org/10.1111/bjd.13670.
CAS
Article
PubMed
Google Scholar
Flora A, Kozera E, Frew JW. Pyoderma gangrenosum: a systematic review of the molecular characteristics of disease. Exp Dermatol. 2022. https://doi.org/10.1111/exd.14534.10.1111/exd.14534.
Article
PubMed
Google Scholar
Garcovich S, De Simone C, Berti E, Marzano AV. Drug management of neutrophilic dermatoses. Expert Rev Clin Pharmacol. 2017;10(10):1119–28. https://doi.org/10.1080/17512433.2017.1356719.
CAS
Article
PubMed
Google Scholar
Herberger K, Dissemond J, Hohaus K, Schaller J, Anastasiadou Z, Augustin M. Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients. Br J Dermatol. 2016;175(5):1070–2. https://doi.org/10.1111/bjd.14619.
CAS
Article
PubMed
Google Scholar
Afifi L, Ortega-Loayza AG, Shinkai K. Management of classic ulcerative pyoderma gangrenosum. Cutis. 2020;106(3):119-E3. https://doi.org/10.12788/cutis.0076.
Article
PubMed
Google Scholar
Orfaly VE, Reese AM, Friedman M, Latour E, Ortega-Loayza AG. Pyoderma gangrenosum study pilot registry: the first step to a better understanding. Wound Repair Regen. 2022. https://doi.org/10.1111/wrr.13005 (Epub ahead of print, 1 Apr 2022).
Article
PubMed
Google Scholar
Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13. https://doi.org/10.1016/j.mce.2010.04.005.
CAS
Article
PubMed
PubMed Central
Google Scholar
Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3(3):149–58. https://doi.org/10.2165/00128071-200203030-00002.
Article
PubMed
Google Scholar
Kolios AGA, Gübeli A, Meier B, et al. Clinical disease patterns in a regional Swiss cohort of 34 pyoderma gangrenosum patients. Dermatology. 2017;233(4):268–76. https://doi.org/10.1159/000481432.
CAS
Article
PubMed
Google Scholar
Vacas AS, Torre AC, Bollea-Garlatti ML, Warley F, Galimberti RL. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients. Int J Dermatol. 2017;56(4):386–91. https://doi.org/10.1111/ijd.13591.
Article
PubMed
Google Scholar
Marzano AV, Trevisan V, Lazzari R, Crosti C. Pyoderma gangrenosum: study of 21 patients and proposal of a ‘clinicotherapeutic’ classification. J Dermatol Treat. 2011;22(5):254–60. https://doi.org/10.3109/09546631003686069.
Article
Google Scholar
Ehling A, Karrer S, Klebl F, Schäffler A, Müller-Ladner U. Therapeutic management of pyoderma gangrenosum. Arthritis Rheum. 2004;50(10):3076–84. https://doi.org/10.1002/art.20559.
Article
PubMed
Google Scholar
Tapia C, Nessel TA, Zito PM. Cyclosporine [updated 2021 Nov 15]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan. https://www.ncbi.nlm.nih.gov/books/NBK482450/. Accessed 16 May 2022.
Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial [published correction appears in BMJ. 2017 Mar 21;356:j1462]. BMJ. 2015;350: h2958. https://doi.org/10.1136/bmj.h2958.
Article
PubMed
PubMed Central
Google Scholar
Mason JM, Thomas KS, Ormerod AD, et al. Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. Br J Dermatol. 2017;177(6):1527–36. https://doi.org/10.1111/bjd.15561.
CAS
Article
PubMed
PubMed Central
Google Scholar
Vidal D, Puig L, Gilaberte M, Alomar A. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J Dermatol Treat. 2004;15(3):146–52. https://doi.org/10.1080/09546630410031909.
Article
Google Scholar
Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145–54. https://doi.org/10.1038/s41584-020-0373-9.
CAS
Article
PubMed
Google Scholar
Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis. 1996;57(5):326–8.
CAS
PubMed
Google Scholar
Loloi J, MacDonald SM. Pyoderma gangrenosum of the penis. Can J Urol. 2021;28(1):10560–4.
PubMed
Google Scholar
Sardana K, Bajaj S, Bose SK. Successful treatment of PAPA syndrome with minocycline, dapsone, deflazacort and methotrexate: a cost-effective therapy with a 2-year follow-up. Clin Exp Dermatol. 2019;44(5):577–9. https://doi.org/10.1111/ced.13792.
CAS
Article
PubMed
Google Scholar
Wang LL, Micheletti RG. Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: a retrospective chart review. J Am Acad Dermatol. 2020;82(2):507–10. https://doi.org/10.1016/j.jaad.2019.09.012.
Article
PubMed
Google Scholar
Vekic DA, Woods J, Lin P, Cains GD. SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature. Int J Dermatol. 2018;57(1):10–8. https://doi.org/10.1111/ijd.13740.
Article
PubMed
Google Scholar
Spangler JG. Pyoderma gangrenosum in a patient with psoriatic arthritis. J Am Board Fam Pract. 2001;14(6):466–9.
CAS
PubMed
Google Scholar
Del Puerto C, Navarrete-Dechent CP, Carrasco-Zuber JE, Vera-Kellet C. Intralesional methotrexate as an adjuvant treatment for pyoderma gangrenosum: a case report. Indian J Dermatol Venereol Leprol. 2017;83(2):277. https://doi.org/10.4103/0378-6323.186497.
Article
PubMed
Google Scholar
Oğuz O, Keskin S. Use of mycophenolate mofetil in dermatology. J Turk Acad Dermatol. 2007;1(4):71401r.
Google Scholar
Mydlarski PR. Mycophenolate mofetil: a dermatologic perspective. Skin Ther Lett. 2005;10(3):1–6.
CAS
Google Scholar
Li J, Kelly R. Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2013;69(4):565–9. https://doi.org/10.1016/j.jaad.2013.05.028.
CAS
Article
PubMed
Google Scholar
Lee MR, Cooper AJ. Mycophenolate mofetil in pyoderma gangrenosum. J Dermatol Treat. 2004;15(5):303–7. https://doi.org/10.1080/09546630410020154.
CAS
Article
Google Scholar
Husein-ElAhmed H, Callejas-Rubio JL, Ríos Fernandez R, Ortego CN. Effectiveness of mycophenolic acid in refractory pyoderma gangrenosum. J Clin Rheumatol. 2010;16(7):346–7. https://doi.org/10.1097/RHU.0b013e3181f6059f.
Article
PubMed
Google Scholar
Young JN, Elgash M, Ortega-Loayza AG. Hidden in plain sight: considerations for an ulcer of the scalp. Head Neck. 2022;44(4):E11-5. https://doi.org/10.1002/hed.26988.
Article
PubMed
Google Scholar
Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;55(3):369–89. https://doi.org/10.1016/j.jaad.2005.07.059.
Article
PubMed
Google Scholar
Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020;16(3):167–78. https://doi.org/10.1038/s41584-020-0374-8.
CAS
Article
PubMed
Google Scholar
Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000;79(1):37–46. https://doi.org/10.1097/00005792-200001000-00004.
CAS
Article
Google Scholar
August PJ, Wells GC. Pyoderma gangrenosum treated with azathioprine and prednisolone. Br J Dermatol. 1974;91:80–2.
Article
Google Scholar
Yoon KH. Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol. 2010;2010: 686480. https://doi.org/10.1155/2010/686480.
CAS
Article
PubMed
PubMed Central
Google Scholar
Abu-Elmagd K, Jegasothy BV, Ackerman CD, et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991;23(6):3328–9.
CAS
PubMed
PubMed Central
Google Scholar
Sadati MS, Dastgheib L, Aflaki E. Recalcitrant cases of pyoderma gangrenosum, responding dramatically to systemic tacrolimus. G Ital Dermatol Venereol. 2017;152(3):308–10. https://doi.org/10.23736/S0392-0488.17.04876-3.
Article
PubMed
Google Scholar
Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103–24. https://doi.org/10.1007/s00403-013-1409-7.
CAS
Article
PubMed
Google Scholar
Din RS, Tsiaras WG, Li DG, Mostaghimi A. Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review. J Drugs Dermatol. 2018;17(10):1058–60.
CAS
PubMed
Google Scholar
Marzano AV, Ramoni S, Caputo R. Amicrobial pustulosis of the folds: report of 6 cases and a literature review. Dermatology. 2008;216(4):305–11. https://doi.org/10.1159/000113942.
Article
PubMed
Google Scholar
Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M. Cytokine and Chemokine profile in amicrobial pustulosis of the folds: evidence for autoinflammation. Medicine (Baltimore). 2015;94(50): e2301. https://doi.org/10.1097/MD.0000000000002301.
CAS
Article
Google Scholar
Leung YY, Yao Hui LL, Kraus VB. Colchicine: update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341–50. https://doi.org/10.1016/j.semarthrit.2015.06.013.
CAS
Article
PubMed
PubMed Central
Google Scholar
Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S, Zakopoulou N. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology. 2004;209(3):233–6. https://doi.org/10.1159/000079897.
CAS
Article
PubMed
Google Scholar
Domingo S, Solé C, Moliné T, Ferrer B, Cortés-Hernández J. Thalidomide exerts anti-inflammatory effects in cutaneous lupus by inhibiting the IRF4/NF-ҡB and AMPK1/mTOR pathways. Biomedicines. 2021;9(12):1857. https://doi.org/10.3390/biomedicines9121857.
CAS
Article
PubMed
PubMed Central
Google Scholar
Hecker MS, Lebwohl MG. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol. 1998;38(3):490–1. https://doi.org/10.1016/s0190-9622(98)70513-4.
CAS
Article
PubMed
Google Scholar
Farrell AM, Black MM, Bracka A, Bunker CB. Pyoderma gangrenosum of the penis. Br J Dermatol. 1998;138(2):337–40. https://doi.org/10.1046/j.1365-2133.1998.02087.x.
CAS
Article
PubMed
Google Scholar
Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc. 2000;75(8):842–4. https://doi.org/10.4065/75.8.842.
CAS
Article
PubMed
Google Scholar
Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176–89. https://doi.org/10.1038/nri3401.
CAS
Article
PubMed
Google Scholar
Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. Br J Dermatol. 2018;178(2):363–8. https://doi.org/10.1111/bjd.15850.
CAS
Article
PubMed
Google Scholar
Haag CK, Ortega-Loayza AG, Latour E, Keller JJ, Fett NM. Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. J Dermatol Treat. 2020;31(7):723–6. https://doi.org/10.1080/09546634.2019.1606888.
CAS
Article
Google Scholar
de Zwaan SE, Iland HJ, Damian DL. Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin. Australas J Dermatol. 2009;50(1):56–9. https://doi.org/10.1111/j.1440-0960.2008.00506.x.
Article
PubMed
Google Scholar
Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J Gastroenterol. 2006;12(4):520–5. https://doi.org/10.3748/wjg.v12.i4.520.
CAS
Article
PubMed
PubMed Central
Google Scholar
Russo I, Miotto S, Colpo A, et al. Successful treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis. Int Wound J. 2017;14(1):282–4. https://doi.org/10.1111/iwj.12684.
Article
PubMed
Google Scholar
Kanekura T, Kawahara K, Maruyama I, Kanzaki T. Treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis. Ther Apher Dial. 2005;9(4):292–6. https://doi.org/10.1111/j.1744-9987.2005.00284.x.
Article
PubMed
Google Scholar
Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome [published correction appears in Clin Exp Immunol. 2015 Jul;181(1):188]. Clin Exp Immunol. 2014;178(1):48–56. https://doi.org/10.1111/cei.12394.
CAS
Article
PubMed
PubMed Central
Google Scholar
Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther. 2013;38(6):563–72. https://doi.org/10.1111/apt.12431.
CAS
Article
PubMed
Google Scholar
Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J. 2019;16(2):511–21. https://doi.org/10.1111/iwj.13067.
Article
PubMed
PubMed Central
Google Scholar
McKenzie F, Cash D, Gupta A, Cummings LW, Ortega-Loayza AG. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatol Treat. 2019;30(3):264–76. https://doi.org/10.1080/09546634.2018.1506083.
CAS
Article
Google Scholar
Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191–211. https://doi.org/10.2165/11595240-000000000-00000.
Article
PubMed
Google Scholar
Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9. https://doi.org/10.1136/gut.2005.074815.
CAS
Article
PubMed
PubMed Central
Google Scholar
Yamamoto T. An update on adalimumab for pyoderma gangrenosum. Drugs Today (Barc). 2021;57(9):535–42. https://doi.org/10.1358/dot.2021.57.9.3293619.
CAS
Article
Google Scholar
Cinotti E, Labeille B, Perrot JL, Pallot-Prades B, Cambazard F. Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis. Clin Exp Dermatol. 2014;39(6):750–1. https://doi.org/10.1111/ced.12393.
CAS
Article
PubMed
Google Scholar
Hurabielle C, Schneider P, Baudry C, Bagot M, Allez M, Viguier M. Certolizumab pegol: a new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s disease. J Dermatol Treat. 2016;27(1):67–9. https://doi.org/10.3109/09546634.2015.1034075.
CAS
Article
Google Scholar
Pender TM, Ayandibu G, Van Voorhees AS. Certolizumab for the treatment of localized pyoderma gangrenosum associated with Crohn’s disease: a case report. Dermatol Ther. 2020;33(6): e14352. https://doi.org/10.1111/dth.14352.
Article
PubMed
Google Scholar
Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol. 2012;67(5):e237-8. https://doi.org/10.1016/j.jaad.2012.04.045.
Article
PubMed
Google Scholar
Skalkou A, Manoli SM, Sachinidis A, et al. Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab. Rheumatol Int. 2018;38(1):161–7. https://doi.org/10.1007/s00296-017-3861-8.
CAS
Article
PubMed
Google Scholar
Diotallevi F, Campanati A, Radi G, et al. Pyoderma gangrenosum successfully treated with golimumab: case report and review of the literature. Dermatol Ther. 2019;32(4): e12928. https://doi.org/10.1111/dth.12928.
Article
PubMed
Google Scholar
Liu FC, Liu NT, Huang TY. Ulcerative colitis with refractory pyoderma gangrenosum. QJM Int J Med. 2020;113(8):567–8. https://doi.org/10.1093/qjmed/hcaa078.
Article
Google Scholar
Russi L, Scharl M, Rogler G, Biedermann L. The efficacy and safety of golimumab as third- or fourth-line anti-TNF therapy in patients with refractory Crohn’s disease: a case series. Inflamm Intest Dis. 2017;2(2):131–8. https://doi.org/10.1159/000481400.
Article
PubMed
PubMed Central
Google Scholar
Kolios AG, Maul JT, Meier B, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015;173(5):1216–23. https://doi.org/10.1111/bjd.14037.
CAS
Article
PubMed
Google Scholar
Ben Abdallah H, Fogh K, Vestergaard C, Bech R. Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review. Dermatology. 2021. https://doi.org/10.1159/000519320.
Article
PubMed
Google Scholar
Macleod T, Berekmeri A, Bridgewood C, Stacey M, McGonagle D, Wittmann M. The immunological impact of IL-1 family cytokines on the epidermal barrier. Front Immunol. 2021;12: 808012. https://doi.org/10.3389/fimmu.2021.808012.
Article
PubMed
PubMed Central
Google Scholar
Lukens JR, Vogel P, Johnson GR, et al. RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3. Nature. 2013;498(7453):224–7. https://doi.org/10.1038/nature12174.
CAS
Article
PubMed
PubMed Central
Google Scholar
Lukens JR, Kanneganti TD. SHP-1 and IL-1α conspire to provoke neutrophilic dermatoses. Rare Dis. 2014;2: e27742. https://doi.org/10.4161/rdis.27742.
Article
PubMed
PubMed Central
Google Scholar
Tartey S, Gurung P, Dasari TK, Burton A, Kanneganti TD. ASK1/2 signaling promotes inflammation in a mouse model of neutrophilic dermatosis. J Clin Investig. 2018;128(5):2042–7. https://doi.org/10.1172/JCI98446.
Article
PubMed
PubMed Central
Google Scholar
Tartey S, Gurung P, Samir P, Burton A, Kanneganti TD. Cutting edge: dysregulated CARD9 signaling in neutrophils drives inflammation in a mouse model of neutrophilic dermatoses. J Immunol. 2018;201(6):1639–44. https://doi.org/10.4049/jimmunol.1800760.
CAS
Article
PubMed
Google Scholar
Nesterovitch AB, Gyorfy Z, Hoffman MD, et al. Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses. Am J Pathol. 2011;178(4):1434–41. https://doi.org/10.1016/j.ajpath.2010.12.035.
CAS
Article
PubMed
PubMed Central
Google Scholar
Nesterovitch AB, Szanto S, Gonda A, et al. Spontaneous insertion of a b2 element in the ptpn6 gene drives a systemic autoinflammatory disease in mice resembling neutrophilic dermatosis in humans. Am J Pathol. 2011;178(4):1701–14. https://doi.org/10.1016/j.ajpath.2010.12.053.
CAS
Article
PubMed
PubMed Central
Google Scholar
Nesterovitch AB, Arbieva Z, Toth DM, Tharp MD, Glant TT. A differential gene expression study: Ptpn6 (SHP-1)-insufficiency leads to neutrophilic dermatosis-like disease (NDLD) in mice. J Dermatol Sci. 2016;83(1):17–25. https://doi.org/10.1016/j.jdermsci.2016.03.005.
CAS
Article
PubMed
Google Scholar
McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892–906. https://doi.org/10.1016/j.immuni.2019.03.021.
CAS
Article
PubMed
PubMed Central
Google Scholar
Herberger K, Dissemond J, Brüggestrat S, Sorbe C, Augustin M. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum: analysis of 52 patients. J Dtsch Dermatol Ges. 2019;17(1):32–41. https://doi.org/10.1111/ddg.13741.
Article
PubMed
Google Scholar
Moreno García M, Madrid González M, Prada Lobato JM. Secukinumab for pyoderma gangrenosum: a case report. Med Clin (Barc). 2019;152(6):246. https://doi.org/10.1016/j.medcli.2018.06.011.
Article
Google Scholar
McPhie ML, Kirchhof MG. Pyoderma gangrenosum treated with secukinumab: a case report. SAGE Open Med Case Rep. 2020. https://doi.org/10.1177/2050313X20940430.
Article
PubMed
PubMed Central
Google Scholar
Huang CM, Tsai TF. Use of brodalumab for the treatment of pyoderma gangrenosum: a case report. Dermatol Sin. 2021;39(1):57. https://doi.org/10.4103/ds.ds_40_20.
Article
Google Scholar
Tee MW, Avarbock AB, Ungar J, Frew JW. Rapid resolution of pyoderma gangrenosum with brodalumab therapy. JAAD Case Rep. 2020;6(11):1167–9. https://doi.org/10.1016/j.jdcr.2020.08.033.
Article
PubMed
PubMed Central
Google Scholar
Lauffer F, Seiringer P, Böhmer D, Oesterlin C, Eyerich K. 044 Safety and efficacy of anti-IL-17 (secukinumab) for the treatment of pyoderma gangrenosum. J Investig Dermatol. 2021;141(10):S156. https://doi.org/10.1016/j.jid.2021.08.046.
Article
Google Scholar
Kaffenberger BH. An open-label, proof-of-concept study of ixekizumab in the treatment of pyoderma gangrenosum. Ohio State University. https://www.clinicaltrials.gov/ct2/show/NCT03137160. Accessed 16 May 2022.
Sadik CD, Thieme M, Zillikens D, Terheyden P. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab. J Eur Acad Dermatol Venereol. 2019;33(11):e406-7. https://doi.org/10.1111/jdv.15714.
CAS
Article
PubMed
Google Scholar
Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical reactions to biologic therapy in psoriasis: a review of the literature. Actas Dermosifiliogr (Engl Ed). 2018;109(9):791–800. https://doi.org/10.1016/j.ad.2018.04.003.
CAS
Article
PubMed
Google Scholar
Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2(2): e000239. https://doi.org/10.1136/rmdopen-2015-000239.
Article
PubMed
PubMed Central
Google Scholar
Wollina U, Schönlebe J, Fürll C. Pyoderma gangrenosum induced by secukinumab: a late paradoxical drug reaction. Dermatol Ther. 2020;33(1): e13161. https://doi.org/10.1111/dth.13161.
CAS
Article
PubMed
Google Scholar
Jin K, Matsuzaki Y, Akasaka E, Nakano H, Sawamura D. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. J Dermatol. 2019;46(3):e108-9. https://doi.org/10.1111/1346-8138.14611.
Article
PubMed
Google Scholar
Pollack IR, Wolner ZJ, Hammett J, Swerlick RA. Pyoderma gangrenosum in a patient on ixekizumab. JAAD Case Rep. 2021;16:152–4. https://doi.org/10.1016/j.jdcr.2021.08.021.
Article
PubMed
PubMed Central
Google Scholar
Petty AJ, Whitley MJ, Balaban A, Ellington K, Marano AL. Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Rep. 2020;6(8):731–3. https://doi.org/10.1016/j.jdcr.2020.06.011.
Article
PubMed
PubMed Central
Google Scholar
Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147(10):1203–5. https://doi.org/10.1001/archdermatol.2011.168.
Article
PubMed
Google Scholar
Westerdahl JS, Nusbaum KB, Chung CG, Kaffenberger BH, Ortega-Loayza AG. Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes. J Dermatol Treat. 2021. https://doi.org/10.1080/09546634.2021.1937475.
Article
Google Scholar
Baier C, Barak O. Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum. JAAD Case Rep. 2020;8:43–6. https://doi.org/10.1016/j.jdcr.2020.12.005.
Article
PubMed
PubMed Central
Google Scholar
Reese AM, Erickson K, Reed KB, Ortega-Loayza AG. Modified dose of guselkumab for treatment of pyoderma gangrenosum. JAAD Case Rep. 2022;21:38–42. https://doi.org/10.1016/j.jdcr.2021.11.030.
Article
PubMed
PubMed Central
Google Scholar
Burgdorf B, Schlott S, Ivanov IH, Dissemond J. Successful treatment of a refractory pyoderma gangrenosum with risankizumab. Int Wound J. 2020;17(4):1086–8. https://doi.org/10.1111/iwj.13359.
Article
PubMed
PubMed Central
Google Scholar
Rafail S, Kourtzelis I, Foukas PG, et al. Complement deficiency promotes cutaneous wound healing in mice. J Immunol. 2015;194(3):1285–91. https://doi.org/10.4049/jimmunol.1402354.
CAS
Article
PubMed
Google Scholar
Sun S, Zhao G, Liu C, et al. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis. 2015;60(4):586–95. https://doi.org/10.1093/cid/ciu887.
CAS
Article
PubMed
Google Scholar
Giamarellos-Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br J Dermatol. 2020;183(1):176–8. https://doi.org/10.1111/bjd.18877.
CAS
Article
PubMed
Google Scholar
InflaRx N.V. 10-2021-InflaRx announces positive data from third cohort of phase IIa open-label study with vilobelimab in pyoderma gangrenosum. https://www.inflarx.de/Home/Investors/Press-Releases/10-2021-InflaRx-Announces-Positive-Data-from-Third-Cohort-of-Phase-IIa-Open-Label-Study-with-Vilobelimab-in-Pyoderma-Gangraenosum-0.html. Accessed 29 Dec 2021.
Schlapbach C, Navarini AA. The continuing evolution of targeted therapy for inflammatory skin disease. Semin Immunopathol. 2016;38(1):123–33. https://doi.org/10.1007/s00281-015-0524-2.
CAS
Article
PubMed
Google Scholar
Kozono K, Nakahara T, Kikuchi S, Itoh E, Kido-Nakahara M, Furue M. Pyoderma gangrenosum with increased levels of serum cytokines. J Dermatol. 2015;42(12):1186–8. https://doi.org/10.1111/1346-8138.12970.
Article
PubMed
Google Scholar
Kawakami T, Yamazaki M, Soma Y. Reduction of interleukin-6, interleukin-8, and anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis. Am J Gastroenterol. 2009;104(9):2363–4. https://doi.org/10.1038/ajg.2009.271.
Article
PubMed
Google Scholar
Lee WS, Choi YJ, Yoo WH. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J Eur Acad Dermatol Venereol. 2017;31(2):e75-7. https://doi.org/10.1111/jdv.13736.
Article
PubMed
Google Scholar
Choong DJ, Ng JL, Vinciullo C. Pyoderma gangrenosum associated with Takayasu’s arteritis in a young Caucasian woman and response to biologic therapy with tocilizumab. JAAD Case Rep. 2021;9:4–6. https://doi.org/10.1016/j.jdcr.2020.12.034.
Article
PubMed
PubMed Central
Google Scholar
Borgia F, Sutera D, Spagnolo A, et al. Onset of pyoderma gangrenosum after tocilizumab therapy for Takayasu arteritis: a new undescribed paradoxical reaction. Br J Clin Pharmacol. 2021;87(8):3378–9. https://doi.org/10.1111/bcp.14756.
Article
PubMed
Google Scholar
Choong DJ, Tan E. Does tocilizumab have a role in dermatology? A review of clinical applications, its adverse side effects and practical considerations. Dermatol Ther. 2021;34(4): e14990. https://doi.org/10.1111/dth.14990.
CAS
Article
PubMed
Google Scholar
Hsu DH, Shi JD, Homola M, et al. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Transplantation. 1999;68(4):545–54. https://doi.org/10.1097/00007890-199908270-00018.
CAS
Article
PubMed
Google Scholar
Lorincz M, Kleszky M, Szalóki T Jr, Szalóki T. Refrakter pyoderma gangraenosum sikeres visilizumabkezelése colitis ulcerosás betegben. Orv Hetil. 2010;151(4):144–7. https://doi.org/10.1556/OH.2010.28786.
Article
PubMed
Google Scholar
Sandborn WJ, Colombel JF, Frankel M, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 2010;59(11):1485–92. https://doi.org/10.1136/gut.2009.205443.
CAS
Article
PubMed
Google Scholar
Carmona-Rivera C, O’Neil LJ, Patino-Martinez E, et al. Autoantibodies present in hidradenitis suppurativa correlate with disease severity and promote the release of proinflammatory cytokines in macrophages. J Investig Dermatol. 2022;142(3 Pt B):924–35. https://doi.org/10.1016/j.jid.2021.07.187.
CAS
Article
PubMed
Google Scholar
Sen M, Dogra S, Rathi M, Sharma A. Successful treatment of large refractory pyoderma gangrenosum-like presentation of granulomatosis with polyangiitis by rituximab. Int J Rheum Dis. 2017;20(12):2200–2. https://doi.org/10.1111/1756-185X.12882.
Article
PubMed
Google Scholar
Murthy RK, Jackson J, Chatham WW, Sami N. Extensive pyoderma gangrenosum associated with granulomatosis with polyangiitis with both responsive to rituximab. J Clin Rheumatol. 2016;22(7):393–5. https://doi.org/10.1097/RHU.0000000000000447.
Article
PubMed
Google Scholar
DaCunha M, Siscos S, Downing M, Tarantino I, Hall J. Pyoderma gangrenosum controlled with rituximab. JAAD Case Rep. 2019;5(7):593–5. https://doi.org/10.1016/j.jdcr.2019.04.019.
Article
PubMed
PubMed Central
Google Scholar
Croitoru D, Nathanielsz N, Seigel K, et al. Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: a systematic review. J Am Acad Dermatol. 2021. https://doi.org/10.1016/j.jaad.2021.12.028.
Article
PubMed
Google Scholar
Lytvyn Y, Mufti A, Maliyar K, Sachdeva M, Yeung J. Onset of pyoderma gangrenosum in patients on biologic therapies: a systematic review. Adv Skin Wound Care. 2022. https://doi.org/10.1097/01.ASW.0000820252.96869.8e (Epub ahead of print).
Article
PubMed
Google Scholar
Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10(12):1437–44. https://doi.org/10.1093/ecco-jcc/jjw092.
Article
PubMed
Google Scholar
Fleisher M, Marsal J, Lee SD, et al. Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci. 2018;63(4):825–33. https://doi.org/10.1007/s10620-018-4971-1.
CAS
Article
PubMed
PubMed Central
Google Scholar
Groudan K, Gupta K, Singhania R. Vedolizumab (Entyvio®) for the treatment of pyoderma gangrenosum in a Crohn’s disease Patient. Cureus. 2021;13(1): e12582. https://doi.org/10.7759/cureus.12582.
Article
PubMed
PubMed Central
Google Scholar
Kim SB, Diaz L, Abreu M. Vedolizumab-induced pyoderma gangrenosum in a patient with ulcerative colitis: 2009. Am J Gastroenterol. 2017;112:S1106-7. https://doi.org/10.14309/00000434-201710001-02010.
Article
Google Scholar
Yeh JE, Tsiaras WG. Intractable pyoderma gangrenosum in a Crohn’s disease patient on vedolizumab. JAAD Case Rep. 2017;3(2):110–2. https://doi.org/10.1016/j.jdcr.2017.01.012.
Article
PubMed
PubMed Central
Google Scholar
Shibuya T, Haga K, Saeki M, et al. Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis. J Clin Apher. 2020;35(5):488–92. https://doi.org/10.1002/jca.21821.
Article
PubMed
Google Scholar
Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048. https://doi.org/10.3389/fphar.2018.01048.
CAS
Article
PubMed
PubMed Central
Google Scholar
Zgraggen A, Maul LV, Hasler P, Mueller RB. Pyoderma gangrenosum and palisaded neutrophilic granulomatous dermatitis in a patient with rheumatoid arthritis treated with apremilast. Ann Clin Case Rep. 2020;5:1807.
Google Scholar
Laird ME, Tong LX, Lo Sicco KI, Kim RH, Meehan SA, Franks AG Jr. Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum. JAAD Case Rep. 2017;3(3):228–9. https://doi.org/10.1016/j.jdcr.2017.02.019.
Article
PubMed
PubMed Central
Google Scholar
Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017;47(7):1096–107. https://doi.org/10.1002/eji.201646680.
CAS
Article
PubMed
Google Scholar
Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. https://doi.org/10.3389/fimmu.2019.02847.
CAS
Article
PubMed
PubMed Central
Google Scholar
Alves de Medeiros AK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;11(10): e0164080. https://doi.org/10.1371/journal.pone.0164080.
CAS
Article
PubMed
PubMed Central
Google Scholar
DeFilippis EM, Feldman SR, Huang WW. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol. 2015;172(6):1487–97. https://doi.org/10.1111/bjd.13493.
CAS
Article
PubMed
Google Scholar
Palanivel JA, Macbeth AE, Levell NJ. Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation. Clin Exp Dermatol. 2013;38(1):44–6. https://doi.org/10.1111/j.1365-2230.2012.04375.x.
CAS
Article
PubMed
Google Scholar
Hideki M, Tetsurou T, Sakae F, Kensei K, Makoto O, Toshinobu K. Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2V617F), showing poor prognosis. Eur J Dermatol. 2013;23(2):256–7. https://doi.org/10.1684/ejd.2013.1956.
Article
PubMed
Google Scholar
Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR. Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol. 2021;46(6):1082–5. https://doi.org/10.1111/ced.14683.
CAS
Article
PubMed
Google Scholar
Montagnon CM, Fracica EA, Patel AA, et al. Pyoderma gangrenosum in hematologic malignancies: a systematic review. J Am Acad Dermatol. 2020;82(6):1346–59. https://doi.org/10.1016/j.jaad.2019.09.032.
Article
PubMed
Google Scholar
Shanmugam VK, McNish S, Shara N, et al. Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi®). J Foot Ankle Surg. 2013;52(6):781–5. https://doi.org/10.1053/j.jfas.2013.07.003.
Article
PubMed
PubMed Central
Google Scholar
Nasifoglu S, Heinrich B, Welzel J. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol. 2018;179(2):504–5. https://doi.org/10.1111/bjd.16468.
CAS
Article
PubMed
Google Scholar
Scheinberg M, Machado LA, Castro M, LG, Ferreira SB, Michalany N. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun. 2021;4: 100099. https://doi.org/10.1016/j.jtauto.2021.100099.
CAS
Article
PubMed
PubMed Central
Google Scholar
ClinicalTrials.gov. Baricitinib in the treatment of adults with pyoderma gangrenosum (PG). https://clinicaltrials.gov/ct2/show/NCT04901325. Accessed 5 Mar 2022.
Thomas KS, Ormerod AD, Craig FE, et al. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. J Am Acad Dermatol. 2016;75(5):940–9. https://doi.org/10.1016/j.jaad.2016.06.016.
Article
PubMed
Google Scholar
Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40(9):1256–65. https://doi.org/10.7164/antibiotics.40.1256.
CAS
Article
Google Scholar
Marzano AV, Trevisan V, Lazzari R, Crosti C. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. J Dermatol Treat. 2010;21(3):140–3. https://doi.org/10.3109/09546630903268239.
CAS
Article
Google Scholar
Schuppe HC, Homey B, Assmann T, Martens R, Ruzicka T. Topical tacrolimus for pyoderma gangrenosum. Lancet. 1998;351(9105):832. https://doi.org/10.1016/S0140-6736(05)78962-5.
CAS
Article
PubMed
Google Scholar
Wollina U. Letter to the editor: Temporary renal insufficiency associated with topical tacrolimus treatment of multilocal pyoderma gangrenosum. J Dermatol Case Rep. 2013;7(3):106–7. https://doi.org/10.3315/jdcr.2013.1154.
Article
PubMed
PubMed Central
Google Scholar
Cecchi R, Pavesi M, Bartoli L, Brunetti L. Successful treatment of localized pyoderma gangrenosum with topical pimecrolimus. J Cutan Med Surg. 2012;16(5):295–7. https://doi.org/10.1177/120347541201600503.
Article
PubMed
Google Scholar
Bellini V, Simonetti S, Lisi P. Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%. J Eur Acad Dermatol Venereol. 2008;22(1):113–5. https://doi.org/10.1111/j.1468-3083.2007.02280.x.
CAS
Article
PubMed
Google Scholar
Azizan NZ, Gangaram HB, Hussein SH. A novel therapy for the treatment of pyoderma gangrenosum. Med J Malays. 2008;63(1):51–4.
CAS
Google Scholar
Strunck JL, Cutler B, Latour E, Seminario-Vidal L, Ortega-Loayza AG. Wound care dressings for pyoderma gangrenosum. J Am Acad Dermatol. 2022;86(2):458–60. https://doi.org/10.1016/j.jaad.2021.09.053.
Article
PubMed
Google Scholar
Croitoru D, Naderi-Azad S, Sachdeva M, Piguet V, Alavi A. A wound care specialist’s approach to pyoderma gangrenosum. Adv Wound Care (New Rochelle). 2020;9(12):686–94. https://doi.org/10.1089/wound.2020.1168.
Article
PubMed
PubMed Central
Google Scholar
Janowska A, Oranges T, Fissi A, Davini G, Romanelli M, Dini V. PG-TIME: a practical approach to the clinical management of pyoderma gangrenosum. Dermatol Ther. 2020;33(3): e13412. https://doi.org/10.1111/dth.13412.
CAS
Article
PubMed
Google Scholar
Eisendle K, Thuile T, Deluca J, Pichler M. Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and skin grafting, including xenografts: personal experience and comprehensive review on 161 cases. Adv Wound Care (New Rochelle). 2020;9(7):405–25. https://doi.org/10.1089/wound.2020.1160.
Article
PubMed
PubMed Central
Google Scholar
Pichler M, Larcher L, Holzer M, et al. Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and split thickness skin grafting under adequate immunosuppression is a valuable treatment option: case series of 15 patients. J Am Acad Dermatol. 2016;74(4):760–5. https://doi.org/10.1016/j.jaad.2015.09.009.
Article
PubMed
Google Scholar
Almeida IR, Coltro PS, Gonçalves HOC, et al. The role of negative pressure wound therapy (NPWT) on the treatment of pyoderma gangrenosum: a systematic review and personal experience. Wound Repair Regen. 2021;29(3):486–94. https://doi.org/10.1111/wrr.12910.
Article
PubMed
Google Scholar
Teguh DN, Bol Raap R, Koole A, et al. Hyperbaric oxygen therapy for nonhealing wounds: treatment results of a single center. Wound Repair Regen. 2021;29(2):254–60. https://doi.org/10.1111/wrr.12884.
Article
PubMed
Google Scholar
Altunay I, Kucukunal A, Sarikaya S, Tukenmez DG. A favourable response to surgical intervention and hyperbaric oxygen therapy in pyoderma gangrenosum. Int Wound J. 2014;11(4):350–3. https://doi.org/10.1111/j.1742-481X.2012.01102.x.
Article
PubMed
Google Scholar
Vieira WA, Barbosa LR, Martin LMM. Hyperbaric oxygen therapy as an adjuvant treatment for pyoderma gangrenosum. An Bras Dermatol. 2011;86(6):1193–6.
Article
Google Scholar
de Sousa MR, Moreira MJ, Rosa B, Cotter J. Hyperbaric oxygen therapy for refractory pyoderma gangrenosum: a salvage treatment. BMJ Case Rep. 2021;14(2): e238638. https://doi.org/10.1136/bcr-2020-238638.
Article
Google Scholar
Tutrone WD, Green K, Weinberg JM, Caglar S, Clarke D. Pyoderma gangrenosum: dermatologic application of hyperbaric oxygen therapy. J Drugs Dermatol. 2007;6(12):1214–9.
PubMed
Google Scholar
Moreira C, Lopes S, Cruz MJ, Azevedo F. Topical timolol for the treatment of pyoderma gangrenosum. BMJ Case Rep. 2017;2017:bcr2016218589. https://doi.org/10.1136/bcr-2016-218589.
Article
PubMed
PubMed Central
Google Scholar
Liu DY, Fischer R, Fraga G, Aires DJ. Collagenase ointment and topical timolol gel for treating idiopathic pyoderma gangrenosum. J Am Acad Dermatol. 2014;71(5):e225-6. https://doi.org/10.1016/j.jaad.2014.07.060.
Article
PubMed
Google Scholar
Fonseka HF, Ekanayake SM, Dissanayake M. Two percent topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study. Int Wound J. 2010;7(6):519–23. https://doi.org/10.1111/j.1742-481X.2010.00725.x.
Article
PubMed
PubMed Central
Google Scholar